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OBJECTIVE — Dysregulated apolipoprotein (apo)C-III metabolism may account for hyper-
triglyceridemia and increased cardiovascular risk in the metabolic syndrome. This study inves-
tigated the dose-dependent effect of rosuvastatin on VLDL apoC-III transport in men with the
metabolic syndrome.
RESEARCH DESIGN AND METHODS — Twelve men with the metabolic syndrome
were studied in a randomized double-blind crossover trial of 5-week intervention periods with
placebo, 10 mg rosuvastatin, or 40 mg rosuvastatin, with 2-week placebo washouts between
each period. VLDL apoC-III kinetics were examined using a stable isotope method and com-
partmental modeling at the end of each intervention period.
RESULTS — Compared with placebo, there was a signiﬁcant dose-dependent reduction with
rosuvastatininplasmatriglycerideandVLDLapoC-IIIconcentrations.Rosuvastatinsigniﬁcantly
(P0.05)increasedVLDLapoC-IIIfractionalcatabolicrate(FCR)anddecreaseditsproduction
rate,withasigniﬁcant(P0.05)dose-relatedeffect.With40mgrosuvastatin,changesinVLDL
apoC-III concentration were inversely associated with changes in VLDL apoC-III FCR and
positivelyassociatedwithVLDLapoC-IIIproductionrate(P0.05).ChangesinVLDLapoC-III
concentration and production rate were positively correlated with changes in VLDL apoB con-
centrationandproductionrateandinverselycorrelatedwithVLDLapoBFCR(P0.05).Similar
associations were observed with 10 mg rosuvastatin but were either less or not statistically
signiﬁcant.
CONCLUSIONS — In this study, rosuvastatin decreased the production and increased the
catabolismofVLDLapoC-III,amechanismthataccountedforthesigniﬁcantreductioninVLDL
apoC-III and triglyceride concentrations. This has implications for the management of cardio-
metabolic risk in obese subjects with the metabolic syndrome.
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H
ypertriglyceridemia, a key feature
of the metabolic syndrome, is asso-
ciatedwithincreasedriskofcardio-
vasculardisease(1).Itisthemostconsistent
lipiddisorderinsubjectswithobesityand
type 2 diabetes. Hypertriglyceridemia is
primarily related to dysregulated triglyc-
eride-rich lipoprotein (TRL) metabolism,
including overproduction of VLDL parti-
cles and delayed catabolism of TRLs
and their remnants (2). These abnormal-
ities are a collective consequence of insu-
lin resistance and increased lipid
substrateavailabilityintheliver,aswellas
depressed activities of lipoprotein lipase
(LPL)andhepaticclearancereceptors(3).
Apolipoprotein (apo)–C-III is an 8.8-
kDa glycoprotein synthesized by the liver
and intestines. ApoC-III is highly associ-
ated with hypertriglyceridemia and is a
powerful independent predictor of car-
diovascular disease risk (4). In circula-
tion, apoC-III is associated with TRL and
HDL, exchanging rapidly between these
particles (5). In normolipidemic subjects,
the majority of plasma apoC-III is bound
to HDL, while in hypertriglyceridemic
subjects,themajorityisboundtoTRL(4).
ApoC-III inhibits LPL activity and TRL
remnantuptakebyhepaticlipoproteinre-
ceptors (4). Elevated plasma apoC-III
concentration, and speciﬁcally its accu-
mulation in TRL and their remnants, is
causally related to hypertriglyceridemia
in the metabolic syndrome (6). Further-
more, insulin resistance is associated
with elevated plasma apoC-III concen-
trations (7). Hence, interventions that
target apoC-III metabolism are clini-
cally important.
Statins decrease de novo cholesterol
synthesis, thereby upregulating LDL re-
ceptor activity. This enhances the uptake
of both hepatic and intestinal-derived
TRLs,therebydecreasingtheirconcentra-
tionsinthecirculation(8).Animalstudies
suggest that statins decrease apoC-III
hepatic mRNA expression and plasma
concentrations via the peroxisome prolif-
erator–activated receptor- pathway
(9,10). However, their effect on apoC-III
metabolism in vivo is not known.
Rosuvastatin is a highly efﬁcacious
statin recently shown to decrease the pro-
gression of atherosclerosis in high-risk
subjects (11). In a dose range between 10
and 40 mg, rosuvastatin signiﬁcantly re-
duced plasma LDL cholesterol and tri-
glyceride and increased HDL cholesterol
concentrations in the metabolic syn-
drome(12).Werecentlyreportedthatro-
suvastatin dose-dependently increased
TRLs and decreased fractional catabolic
rates of HDL particles that contain only
apoA-I (LpA-I), consistent with parallel
reduction in plasma triglycerides and an
increase in HDL cholesterol concentra-
tions (13,14). The triglyceride-lowering
effect of rosuvastatin may, in part, be reg-
ulated by the reduction of plasma apoC-
III concentrations (13). However, the
precise mechanism of action of this agent
on VLDL–apoC-III kinetics in the meta-
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examined.
In the present study, we investigated
the dose-related effect of rosuvastatin on
VLDL apoC-III transport in the metabolic
syndrome.Wehypothesizedthatahigher
dose of rosuvastatin would reduce VLDL
apoC-III concentration by a mechanism
that primarily involves decreasing the
production of apoC-III. We also explored
the dose-dependent effect of rosuvastatin
on other markers of TRL metabolism, in-
cluding apoB-48 and apoA-V.
RESEARCH DESIGN AND
METHODS— Twelve Caucasian men
with the metabolic syndrome by the Na-
tional Cholesterol Education Program
AdultTreatmentPanelIII(NCEPATPIII)
deﬁnition(15)wererecruited.Upperlim-
itsforHDLcholesterol1.2mmol/l,LDL
cholesterol 6 mmol/l, and triglycerides
4.5 mmol/l were stipulated to exclude
subjects with genetic hyperlipidemia in-
cluding familial hypercholesterolemia
and familial hypertriglyceridemia and
other secondary causes of severe dyslipi-
demia. Subjects with diabetes (fasting
glucose 7 mmol/l), cardiovascular dis-
ease, renal dysfunction (macroprotein-
uriaand/orserumcreatinine150mol/
l), apoE2/E2 genotype, hypothyroidism,
or abnormal liver or muscle enzymes;
who consumed 30 g alcohol/day; or
whousedlipid-modifyingagentswereex-
cluded. All were nonsmokers and were
consuming ad libitum weight-mainte-
nance diets. Participants provided in-
formed written consent, and the study
was approved by the Ethics Committee of
Royal Perth Hospital.
Study design and clinical protocols
This was a randomized double-blind
three-waycrossovertrial.Eligiblepatients
entered a 4-week run-in diet-stabilizing
period,attheendofwhichtheywereran-
domized to a 5-week intervention period
of 40 mg rosuvastatin, 10 mg rosuvasta-
tin, or placebo. Rosuvastatin was pro-
vided by AstraZeneca (London, U.K.).
Advice was given to continue isocaloric
diets and to maintain a physical activity
constant.Compliancewithstudymedica-
tion was assessed by tablet count.
Allsubjectswereadmittedtothemet-
abolic ward in the morning after a mini-
mum of a 12-h fast. They were studied
semi-recumbent and allowed water only
for the initial 10 h of the study. Venous
blood was collected for biochemical mea-
surements. Body weight and height were
measured and arterial blood pressure was
recorded using a Dinamap1846 SX/P
monitor (Critikon, Tampa, FL). Dietary
intakewasassessedusing24-hdietarydi-
aries and DIET 4 Nutrient Calculation
Software (Xyris Software, Queensland,
Australia).
A single bolus of D3-leucine (5 mg/
kg) was administered intravenously into
an antecubital vein via a Teﬂon cannula.
Blood samples were taken at baseline and
at 5, 10, 20, 30, and 40 min and 1, 1.5, 2,
2.5, 3, 4, 5, 6, 8, and 10 h after isotope
injection. Additional blood samples were
collected in the morning on the 4 follow-
ing days (24, 48, 72, and 96 h) after a
minimum 12-h fast. All the procedures
wererepeatedattheendofeachtreatment
period.
Biochemical analyses
Laboratory methods for measurements of
lipids, lipoproteins, and other biochemi-
calanalyteshavebeenpreviouslydetailed
(13,14). Insulin resistance was calculated
using a homeostasis model assessment
score. VLDL apoC-III values were deter-
mined by electro-immunodiffusion using
a Hydragel LP CIII Electro-immunodiffu-
sion kit (Sebia, France); interassay coefﬁ-
cients of variations (CVs) were 5.0%
(5). Plasma apoB-48 concentrations were
measured by a sandwich enzyme-linked
immunoassay using anti-human apoB-48
monoclonal antibodies (interassay CV
5%). Plasma apoA-V concentration was
determined using a dual-antibody sand-
wich enzyme-linked immunosorbent as-
say (Linco Diagnostic Services).
Isolation of VLDL apoC-III
The methods for the isolation of lipopro-
teins and apoC-III have been previously
described (5). In brief, 3 ml plasma was
used for isolation of 1 ml VLDL (1.006
kg/l) fraction by sequential ultracentrifu-
gation at 40,000 rpm in a Ti 50.4 rotor
(Optima LE-80K; Beckman Coulter, Aus-
tralia). The VLDL samples were then pre-
pared for isoelectric focusing gel
eletrophoresis. VLDL (200 l) from each
time point was delipidated and reconsti-
tuted in 50 l isoelectric focusing sample
buffer (8 M urea; 0.001% wt/vol brom-
phenol blue). ApoC-III was isolated by
preparative isoelectric focusing gel elec-
trophoresis (8 M urea; 7.5% acrylamide;
1.5% ampholytes pH 4–6; 16 h; 200 V;
4°C).Gelswereelectro-blottedontopoly-
vinylidene ﬂuoride membranes (Immo-
bilon; Millipore) at 700 mA for 1 h using
a Hoefer TE 42 transfer unit (Amersham
Biosciences, Australia) and stained with
Coomassie Brilliant Blue R 250 (5).
Measurement of D3-leucine
enrichment in apoC-III1
Isoelectric focusing resolves apoC-III into
three isoforms: apoC-III0, apoC-III1, and
apoC-III2. ApoC-III1 was investigated in
this study because of its greater concen-
tration in plasma and observations from
previousstudiesthatthekineticsofapoC-
III isoforms was similar (16). All refer-
Figure1—CompartmentmodeldescribingapoC-IIItracerkinetics.Leucinetracerisinjectedinto
plasma (compartment 2) and distributes to extravascular compartments 1, 3, and 4. Compart-
ments 1–4 are required to describe leucine tracer kinetics observed in plasma. Compartment 1 is
connected to two intracellular delay compartments (compartment 5 and 6) that account for the
assembly, synthesis, and secretion of apoC-III. Compartment 7 describes the kinetics of VLDL
apoC-III and compartment 8 is an extravascular exchange compartment.
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tothekineticsofapoC-III1.TheapoC-III1
proteinbandswereexcisedfromthepoly-
vinylidene ﬂuoride and hydrolyzed in
200 l 6 M HCl overnight at 110°C in
pyrolysis-cleaned half-dram vials. Sam-
ples are dried at 110°C and derivatized
using a modiﬁed oxazolinone method.
The oxazolinone derivatives are analyzed
by negative ion chemical ionization gas
chromatography–mass spectrometry.
The isotopic enrichment is determined as
the tracer-to-tracee ratio of monitored se-
lected ions at a mass to charge (m/z) ratio
of 212/209. The average coefﬁcient of
variationofapoC-IIItracermeasurement,
including processes associated with isola-
tion of apoC-III from plasma through to
the measurement of isotopic enrichment,
is 5.4% (5).
Kinetic analyses
A model of VLDL apoC-III metabolism
was developed using the SAAM II pro-
gram (SAAM Institute, Seattle, WA) (Fig.
1; 17). The model consists of a four-
compartment subsystem (compartments
1–4) that describes plasma leucine kinet-
ics. This subsystem is connected to two
intrahepatic delay compartments (com-
partments 5 and 6) that account for the
time required for the assembly, synthesis,
and secretion of apoC-III into plasma.
The kinetics of VLDL apoC-III is
described by a plasma compartment
(compartment7)andanextravascularex-
change compartment (compartment 8).
The time for delay compartment 5
(mean  SE 0.52  0.04 h) was shorter
than compartment 6 (1.98  0.25 h);
however, this did not affect estimates of
VLDL apoC-III fractional catabolic rate
(FCR), nor was there any effect of treat-
ment on delay times. FCR of VLDL apoC-
III,equivalenttotheirreversiblelossfrom
compartment 7, was estimated after ﬁt-
ting the model to the VLDL apoC-III
tracer data. The production rate (PR), the
transport rate of apoC-III through the
VLDL pool, was calculated as the product
of FCR and pool size, which equals the
plasma concentration multiplied by
plasma volume; plasma volume was esti-
mated as 4.5% of body weight, with ad-
justmentmadetoaccountforthedecrease
in relative plasma volume with body
weights in the obese range.
Statistical analysis
Skewed variables were logarithmically
transformed where appropriate. Data at
the end of the three treatment periods
were compared using a mixed-effect
model (SAS Proc Mixed; SAS Institute),
which also tested for carry-over, treat-
ment sequence, and time-dependent ef-
fects. There were no signiﬁcant carry-
over, treatment-sequence, or time-
dependent effects. A mixed-effect model
wasalsousedtoexaminethedose-related
effect of rosuvastatin on study variables.
The P values are reported, with statistical
signiﬁcance set at the 5% level. Statistical
associations between changes in variables
were also examined on both doses of ro-
suvastatin using simple, stepwise, and
multiple linear regression methods.
RESULTS— The clinical and bio-
chemicalcharacteristicsofthe12subjects
were reported previously (13,14). They
were centrally obese, insulin resistant,
and dyslipidemic. There were no signiﬁ-
cant treatment effects on body weight,
blood pressure, insulin, glucose, fatty ac-
ids, and homeostasis model assessment
score. Both 10 and 40 mg rosuvastatin
were well tolerated. There were no signif-
icant changes in liver and muscle en-
zymes or serum creatinine, and no
subjects developed dipstick-positive pro-
teinuria. Mean daily dietary intake was as
follows: energy (10,245  575 kJ), total
fat (90.9  6.3g), total carbohydrate
(256  15 g), protein (123  7 g), cho-
lesterol (385  46 mg), and alcohol
(6.5  2.9 g) and did not differ signiﬁ-
cantly between treatment phases.
Table 1 gives the plasma concentra-
tions of lipids, lipoproteins, and apoli-
poproteins on placebo, 10 mg rosuvastatin,
and 40 mg rosuvastatin. Compared with
placebo, rosuvastatin signiﬁcantly de-
creased plasma cholesterol, triglycerides,
LDL cholesterol, and apoB and apoC-III
concentrations and the apoB/apoA-I and
lathosterol-to-cholesterol ratios, with a
signiﬁcant increase in HDL cholesterol
concentration and campesterol-to-
cholesterol ratio. These changes were
greater with 40 mg than with 10 mg ro-
suvastatin, with a statistically signiﬁcant
dose-dependent effect.
Table 2 gives the plasma concentra-
tions and kinetics of VLDL apoC-III on
placebo and on 10 and 40 mg rosuvasta-
tin. Compared with placebo, rosuvastatin
decreased VLDL apoC-III concentration
(10 mg rosuvastatin 22%, 40 mg rosu-
vastatin 45%) and production rate (10
mg rosuvastatin 15%, 40 mg rosuvasta-
tin 25%) and increased VLDL apoC-III
FCR (10 mg rosuvastatin 1 7 % ,4 0m g
Table 1—Lipid, lipoprotein, and apolipoprotein concentrations on placebo, 10 mg rosuvastatin, and 40 mg rosuvastatin
Placebo (P)
10 mg rosuvastatin
(R10)
40 mg rosuvastatin
(R40)
Group difference (P)
Dose effect
(P)
P vs.
R10
P vs.
R40
R10 vs.
R40
Total cholesterol (mmol/l) 5.52  0.25 3.64  0.16 3.20  0.13 0.001 0.001 0.024 0.001
Triglycerides (mmol/l) 2.47  0.32 1.88  0.21 1.44  0.13 0.027 0.001 0.063 0.001
LDL cholesterol (mmol/l) 3.50  0.22 1.78  0.12 1.51  0.10 0.001 0.001 0.063 0.001
HDL cholesterol (mmol/l) 0.94  0.04 0.98  0.05 1.03  0.04 0.227 0.011 0.129 0.011
ApoB (g/l) 1.19  0.05 0.74  0.03 0.65  0.03 0.001 0.001 0.009 0.001
ApoA-I (g/l) 1.22  0.04 1.27  0.04 1.25  0.03 0.090 0.086 0.566 0.276
ApoB/ApoA-I ratio 0.98  0.02 0.58  0.02 0.51  0.03 0.001 0.001 0.006 0.001
ApoC-III (mg/l) 139  9.85 122  8.98 107  4.55 0.045 0.001 0.047 0.011
Lathosterol (mol/l) 24.0  2.64 6.33  0.80 3.42  0.35 0.001 0.001 0.145 0.001
Lathosterol-to-cholesterol ratio 4.36  0.42 1.73  0.19 1.08  0.11 0.001 0.001 0.031 0.001
Campesterol (mol/l) 11.8  1.73 9.84  1.36 10.1  1.30 0.005 0.015 0.609 0.113
Campesterol-to-cholesterol ratio 2.11  0.28 2.74  0.38 3.12  0.36 0.001 0.001 0.016 0.001
Data are means  SE or P.
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cally signiﬁcant dose-dependent effect of
rosuvastatin on VLDL apoC-III concen-
tration, FCR, and PR (Table 1). Rosuvas-
tatin dose-dependently lowered plasma
apoB-48(placebo4.460.25;10mgro-
suvastatin 4.12  0.31; 40 mg rosuvasta-
tin 3.54  0.19; P valuedose  0.002).
Therewasnosigniﬁcanteffectofrosuvas-
tatin on apoA-V concentration (placebo
132  28; 10 mg rosuvastatin 155  34;
40 mg rosuvastatin 103  17; P valuedose
 0.107).
With 40 mg rosuvastatin, the reduc-
tion in VLDL apoC-III concentration was
signiﬁcantly associated with an increase
in VLDL apoC-III FCR (r  0.710, P 
0.01) and a fall in VLDL apoC-III PR (r 
0.939, P  0.01). The changes in VLDL
apoC-III PR and FCR were independent
determinants of change in VLDL apoC-III
concentration (adjusted r
2  98%, P 
0.01). With 10 mg rosuvastatin, the de-
crease in VLDL apoC-III concentration
was signiﬁcantly associated with the re-
duction in VLDL apoC-III PR (r  0.752,
P0.01).ThefallinVLDLapoC-IIIcon-
centration was associated with the in-
crease in VLDL apoC-III FCR, but this
failed to reach statistical signiﬁcance (r 
0.511,P0.08).ThechangesinVLDL
apoC-III PR and FCR were independent
determinants of change in VLDL apoC-III
concentration (adjusted r
2  97%, P 
0.01).
Given the role of apoC-III in regulat-
ing TRL metabolism, associations be-
tween VLDL apoC-III and VLDL apoB
kinetic parameters were explored. Both
VLDL apoC-III and VLDL apoB kinetic
parameters were derived from the same
subjects.Thedose-dependenteffectofro-
suvastatin on apoB-containing lipopro-
teinsinthesesubjectswasreportedearlier
(13). Changes in VLDL apoC-III concen-
tration were signiﬁcantly associated with
changesinVLDLapoBconcentration(r
0.901, P  0.01), FCR (r  0.791, P 
0.002), and PR (r  0.642, P  0.024).
Similar associations were observed be-
tween plasma total apoC-III concentra-
tion and the corresponding VLDL apoB
FCR. Changes in VLDL apoC-III PR were
signiﬁcantly associated with changes in
VLDL apoB concentration (r  0.934,
P  0.01), FCR (r  0.897, P  0.01),
andPR(r0.639,P0.025).Theabove
associations between VLDL apoC-III and
VLDL apoB kinetic parameters were also
seen with 10 mg rosuvastatin but were
not as signiﬁcant.
Additional analysis revealed that
changes in plasma triglycerides were as-
sociated with changes in VLDL apoC-III
concentration, FCR, and PR (r  0.958,
P  0.01; r  0.653, P  0.021; and
r  0.932, P  0.01, respectively); VLDL
apoB concentration, FCR, and PR (r 
0.879, P  0.01; r  0.860, P  0.01;
and r  0.570, P  0.053, respectively);
and plasma apoB-48 concentration (r 
0.586, P  0.045). In a stepwise regres-
sionmodelthatincludedplasmaapoB-48
and VLDL apoB concentrations, VLDL
apoC-III concentration was an indepen-
dent predictor of changes in plasma trig-
lycerides (adjusted r
2  93%, P  0.01).
Furthermore, changes in VLDL apoC-III
FCR and PR were independent determi-
nants for changes in plasma triglyceride
concentrations in a stepwise regression
model that included VLDL apoB FCR and
PR (adjusted r
2  94%, P  0.01).
CONCLUSIONS— We provide new
information on the dose-ranging effect of
rosuvastatin, a potent HMG-CoA (or
3-hydroxy-3-methyl-glutaryl-CoA) re-
ductase inhibitor, on VLDL apoC-III me-
tabolism in subjects with the metabolic
syndrome. We demonstrated that rosuv-
astatin dose-dependently decreased
VLDLapoC-IIIconcentrationsbyincreas-
ing the FCR and decreasing the PR of
VLDL apoC-III. These results add further
to our work on the dose-dependent effect
of rosuvastatin on apoB-containing li-
poproteins and HDL particle kinetics in
the same subjects (13,14).
Hypertriglyceridemia in insulin-
resistant states, including the metabolic
syndrome, results from overproduction
and reduced catabolism of TRL and their
remnants. These kinetic aberrations may
be related to altered VLDL apoC-III me-
tabolism. Previous studies demonstrated
thatoverproductionofVLDLapoC-IIIex-
plained the higher VLDL apoC-III con-
centration in these subjects (17). The
increased VLDL apoC-III concentration
and production rate were associated with
elevated VLDL triglycerides, oversecre-
tion of VLDL apoB, and reduced VLDL
apoB catabolism (17,18). Statins have
been shown to effectively reduce plasma
and VLDL apoC-III concentrations (4).
The effect of statin therapy on VLDL
apoC-IIItransport,however,hasnotbeen
examined.Weextendthesereportsbyex-
amining the dose-related effect of rosuv-
astatin on VLDL apoC-III kinetics in the
metabolic syndrome using a three-way
crossover study design.
Consistent with larger clinical trials,
rosuvastatin dose-dependently reduced
plasma triglyceride concentrations in
subjects with the metabolic syndrome
(12).Thereductioninplasmatriglyceride
concentrations was chieﬂy explained by
thedecreaseinVLDLapoC-IIIconcentra-
tions. This is consistent with previous ob-
servations that reduced apoC-III in TRL
enhances LPL-mediated lipolysis and re-
ceptor-mediated clearance of TRL,
thereby lowering plasma triglyceride lev-
els (4).
We demonstrated, for the ﬁrst time,
that rosuvastatin dose-dependently in-
creased VLDL apoC-III fractional catabo-
lism and reduced VLDL apoC-III
production. Both VLDL apoC-III FCR
and PR were independent determinants
of VLDL apoC-III concentration. The in-
crease in VLDL apoC-III FCR may be ex-
plained, in part, by direct removal of
VLDLapoC-IIIfromcirculationand/orits
redistribution to other lipoproteins, spe-
ciﬁcally HDL. The redistribution of
apoC-III from VLDL to HDL during
LPL-mediated hydrolysis of VLDL tri-
Table 2—Concentrations, FCRs, and PRs for VLDL apoC-III during placebo, 10 mg rosuvastatin, and 40 mg rosuvastatin treatments
Placebo (P)
10 mg rosuvastatin
(R10)
40 mg rosuvastatin
(R40)
Group difference (P)
Dose effect
(P)
P vs.
R10
P vs.
R40
R10 vs.
R40
Concentration (mg/l) 84.6  12.0 64.1  8.9 46.4  4.5 0.041 0.001 0.036 0.001
FCR (pools/day) 0.96  0.06 1.09  0.07 1.28  0.06 0.027 0.001 0.002 0.001
PR (mg   kg
1   day
1) 2.86  0.42 2.42  0.29 2.14  0.19 0.145 0.018 0.298 0.029
Data are means  SE or P.
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back to triglyceride-rich particles are
well established (19). The precise
mechanism of action of rosuvastatin on
VLDLapoC-IIIPRisunclear.Statinshas
been shown to activate the peroxisome
proliferator–activated receptor- path-
way via inhibition of 	-signaling,
thereby repressing apoC-III mRNA ex-
pression and reducing apoC-III synthe-
sisinhumanHepG2hepatomacells(9).
To date, no studies have examined the
effect of statins on apoC-III synthesis in
humans. Further analysis of total
plasma apoC-III kinetics in the same
subjects showed that rosuvastatin re-
duced total plasma apoC-III concentra-
tion by dose-dependently increasing
total plasma apoC-III FCR, with no sig-
niﬁcant changes to total plasma apoC-
III PR (total plasma apoC-III PR is
synonymous with the amount of apoC-
IIIsecretedintoplasmabyboththeliver
and intestine) (E.M.M.O., G.F.W.,
D.C.C., P.H.R.B., unpublished data).
We propose that the reduction in VLDL
apoC-IIIPRmaybeafunctionofaltered
distribution of apoC-III between VLDL
and HDL particles with rosuvastatin
treatment, rather than an effect on
apoC-III gene expression and hence he-
patic or intestinal apoC-III synthesis.
The reduction in CETP mass and ac-
tivity with rosuvastatin may also contrib-
ute to an altered distribution of apoC-III
between VLDL and HDL particles and,
hence, changes to its kinetics by favoring
the formation of smaller VLDL and larger
HDL species (20) with different thermo-
dynamic stability and composition.
The reduction in VLDL apoC-III pro-
duction with rosuvastatin was associated
with the decrease in VLDL apoB concen-
trationandPRandincreaseinVLDLapoB
FCR. The precise reason for a potential
coupling of VLDL apoC-III and VLDL
apoB metabolism remains unclear, but is
consistent with the role of apoC-III as a
regulator of apoB transport. Sundaram et
al.(21)demonstratedthatoverexpression
andhenceoversecretionofapoC-IIIstim-
ulated apoB synthesis, VLDL assembly,
and secretion in McARH7777 cells. Al-
though rosuvastatin signiﬁcantly reduced
VLDL apoC-III PR, there was no impact
on VLDL apoB PR (13), suggesting an un-
couplingofthisassociation.Thisobserva-
tion further reinforces that the persistent
state of insulin resistance in metabolic
syndrome subjects is a powerful pro-
moter of apoB secretion (3).
ApoA-Vmayregulatetriglycerideme-
tabolism, including VLDL assembly, LPL
activity, and VLDL receptor binding (22).
However, the association between
apoA-V and plasma triglycerides remains
contentious(22).Todate,nostudieshave
examined the effect of statin therapy on
apoA-V levels. Rosuvastatin, while signif-
icantly reducing plasma triglycerides, did
not alter apoA-V concentrations in our
study. This may be explained, in part, by
recent evidence suggesting that the pri-
marymetabolicroleofapoA-Visintracel-
lular rather than extracellular (23).
Consistent with this notion, apoA-V was
shown to reduce the lipidation of VLDL
without altering apoB secretion (23). Fu-
ture studies using VLDL triglyceride ki-
netics, coupled with cellular studies, are
warrantedtobetterunderstandtheroleof
apoA-V in vivo.
Our study was restricted to men, and
we did not study type 2 diabetic subjects.
Ourﬁndingsmayapplytowomen,type2
diabeticpatients,andsubjectsofdifferent
ethnicity, although this requires further
investigation. Measurements of lipases in
postheparin plasma may have corrobo-
rated our ﬁndings. The effects of rosuvas-
tatin on apoC-II, a cofactor for LPL,
should also be examined. ApoC-III dis-
plays noncompetitive inhibitory proper-
ties against apoC-II, indicating the
opposing regulatory effects of these two
apolipoproteinsonTRLmetabolism(24).
The ratio of apoC-III to apoC-II may
therefore be a crucial factor in the regula-
tion of triglyceride hydrolysis.
In conclusion, elevated plasma trig-
lycerides are powerful predictors of car-
diovascular disease in the metabolic
syndrome. ApoC-III may account for this
association. Rosuvastatin effectively re-
duces plasma triglycerides by improving
VLDL apoC-III transport in subjects with
the metabolic syndrome. Our ﬁndings
further suggest that these subjects may
derive incremental beneﬁt from higher-
dose rosuvastatin therapy (12). Future
studies should explore whether lifestyle
changes and other pharmacotherapies
can further reduce apoC-III concentra-
tions against the background of rosuvas-
tatin in the metabolic syndrome.
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